Skip Navigation

Shohei Koide, Ph.D.


Professor, Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, and Director, Cancer Biologics, Perlmutter Cancer Center, NYU Langone Health

Shohei Koide, Ph.D., is a Professor of Biologics Design in the Department of Biochemistry and Molecular Pharmacology at the New York University (NYU) Grossman School of Medicine and the Director of Cancer Biologics at the Perlmutter Cancer Center at NYU Langone Health. He is a Fellow of the American Association for the Advancement of Science.

A leader in the field of protein engineering and design, Dr. Koide’s research integrates rational design, directed evolution, structural biology, and cell biology to design highly functional, but still simple, antibodies and other types of target-binding proteins, and applies such synthetic binding proteins as therapeutics and research tools. Dr. Koide is the inventor of the FN3 monobody technology, a widely adopted non-antibody scaffold system, and has established it as an enabling technology for addressing fundamental challenges in chemical, structural, and cellular biology. His current research focuses on the discovery of biologics therapeutics and strategies to control ‘undruggable’ targets.

Previously, Dr. Koide was a Professor of Biochemistry and Molecular Biology at the University of Chicago and served as a scientific co-director of the Chicago Biomedical Consortium. Dr. Koide has published more than 130 peer-reviewed articles and is the inventor of several patent families. He earned his Ph.D., M.S., and B.Sc. degrees from the University of Tokyo, and he was a Human Frontier Science Program Postdoctoral Fellow in Molecular Biophysics at The Scripps Research Institute in La Jolla, CA.